Patents by Inventor Ross G. Clark

Ross G. Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin-like growth factor agonist molecules
    Patent number: 6693079
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6693078
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6689751
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: February 10, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6683053
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6680298
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 20, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6677305
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Method for treating cartilage disorders
    Publication number: 20030211992
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Application
    Filed: October 16, 2002
    Publication date: November 13, 2003
    Applicant: GENENTECH, INC.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C.A.F. Robinson, Nicholas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6645775
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6635619
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 21, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6632794
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6620789
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 16, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C.A.F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6608031
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 19, 2003
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Insulin-like growth factor agonist molecules
    Patent number: 6608028
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: August 19, 2003
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Publication number: 20030139348
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: August 19, 2002
    Publication date: July 24, 2003
    Applicant: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES
    Publication number: 20020111461
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: May 21, 1999
    Publication date: August 15, 2002
    Inventors: TODD C. SOMERS, KATHLEEN A. ELIAS, ROSS G. CLARK, ROBERT S. MCDOWELL, MARK S. STANLEY, JOHN P. BURNIER, THOMAS E. RAWSON
  • Insulin-like growth factor agonist molecules
    Patent number: 6420518
    Abstract: Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: July 16, 2002
    Assignees: Genetech, Inc.
    Inventors: Yvonne Man-yee Chen, Ross G. Clark, Andrea G. Cochran, Henry B. Lowman, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Insulin-like growth factor agonist molecules
    Patent number: 6251865
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: June 26, 2001
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Human growth hormone variants comprising amino acid substitutions
    Patent number: 6136563
    Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: October 24, 2000
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, James A. Wells, Ross G. Clark, Kenneth Olson, Germaine G. Fuh
  • Insulin-like growth factor agonist molecules
    Patent number: 6121416
    Abstract: Compounds are provided that prevent the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: September 19, 2000
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Method for inhibiting growth hormone action
    Patent number: 6057292
    Abstract: Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
    Type: Grant
    Filed: February 24, 1998
    Date of Patent: May 2, 2000
    Assignee: Genentech, Inc.
    Inventors: Brian C. Cunningham, Henry B. Lowman, James A. Wells, Ross G. Clark, Kenneth Olson, Germaine G. Fuh